BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 15975534)

  • 1. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
    Scarpignato C
    Dig Liver Dis; 2005 Jul; 37(7):468-74. PubMed ID: 15893968
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
    Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T
    Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Furuta K; Adachi K; Komazawa Y; Mihara T; Miki M; Azumi T; Fujisawa T; Katsube T; Kinoshita Y
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1581-5. PubMed ID: 16928220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: Helicobacter pylori and gastro-oesophageal reflux disease.
    Delaney B; McColl K
    Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():32-40. PubMed ID: 16042657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
    Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
    Bautista J; Fullerton H; Briseno M; Cui H; Fass R
    Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-week versus two-week H2-receptor antagonist in combination with amoxicillin and tinidazole for eradication of Helicobacter pylori infection.
    Hsu CC; Chen JJ; Hu TH; Lu SN; Changchien CS
    Hepatogastroenterology; 2005; 52(65):1617-21. PubMed ID: 16201128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
    Howden CW; Henning JM; Huang B; Lukasik N; Freston JW
    Am J Gastroenterol; 2001 Jun; 96(6):1704-10. PubMed ID: 11419818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors?
    Rauws EA
    Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):569-73. PubMed ID: 9513835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of anti-ulcer drugs used in Japan on the result of (13)C-urea breath test for the diagnosis of Helicobacter pylori infection.
    Murakami K; Sato R; Okimoto T; Watanabe K; Nasu M; Fujioka T; Kodama M; Kagawa J
    J Gastroenterol; 2003; 38(10):937-41. PubMed ID: 14614600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production.
    Bergman MP; Klinkenberg-Knol EC; Faller G; Aar A; Lakhai W; Vandenbroucke-Grauls CM; Kuipers EJ; Appelmelk BJ
    Aliment Pharmacol Ther; 2005 Apr; 21(8):977-83. PubMed ID: 15813833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].
    Kanayama S
    Nihon Rinsho; 1999 Jan; 57(1):153-6. PubMed ID: 10036954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.